Core Insights - Insmed Inc. (NASDAQ: INSM) has reached an all-time high stock price, driven by a positive business outlook despite an increase in net loss [1][4] Financial Performance - The stock price peaked at $194.70 during intra-day trading, closing at $194.22, reflecting a 16.33% increase [2] - Insmed's revenue from Arikayce, its primary treatment for MAC bacteria infection, is projected to grow by 15-18% to between $420 million and $430 million, an increase from previous estimates of $405 million to $425 million [2] - In Q3, Arikayce revenues rose by 22% to $114.3 million from $93.4 million year-over-year, contributing to a total revenue increase of 52% to $142.3 million [3] - The company’s new treatment, Brinspuri, generated $28.1 million in revenue during the same quarter [3] Losses - Insmed reported a 68% increase in net loss for Q3, amounting to $370 million compared to $220 million in the same period last year [4] - The cumulative net loss for the first nine months of the year reached $948 million, a 40% increase from $678 million in the previous year [4]